A Phase 2 interventional study of Abatacept and Placebo in COVID-19 and SARS-CoV-2, sponsored by Bristol-Myers Squibb. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-07.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 744th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 525th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Recent acute infection defined as:
i) Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not COVID-19 related) ii) Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Abatacept
Other: Placebo
Specified dose on specified days
Also known as: ORENCIA®, BMS-188667
Specified dose on specified days
Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28
The percentage of participants on invasive mechanical ventilation is defined as the delivery of positive pressure to the lungs via an endotracheal tube (or tracheostomy) or death prior to or on day 28.
Time frame: From first dose to 28 days post first dose
Adjusted Mean Change From Baseline in the Ordinal 8-Point Clinical Status Scale on Day 28
Adjusted mean change from baseline based on the following Ordinal 8-point Clinical Status Scale that was proposed for the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) and is recorded by the worst score (lowest number) state for each day: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, on non-invasive mechanical ventilation or high-flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized, limitation on activities and/or requiring home oxygen; 8. Not hospitalized, no limitation on activities Baseline is defined as the last assessment done prior or on Day 1
Time frame: Baseline and on Day 28
Percentage of Participants Who Died
Percentage of participants who died due to any cause. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 1) Death
Time frame: From first dose to 28 days post first dose
Percentage of Participants Alive and Free of Respiratory Failure on Day 28±3
Respiratory failure is defined by the type of resources required as defined by the use of any of these: Mechanical ventilation, extracorporeal membrane oxygenation (ECMO) or oxygen delivery by noninvasive positive pressure or high flow nasal cannula. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities
Time frame: Day 28±3
Percentage of Participants Returned to Room Air on Day 28
Recovery of pulmonary function is assessed by the percentage of participants returned to room air on day 28 after they were oxygen dependent and dependence on oxygen has been noted to be prolonged even after hospital discharge. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 8) Not hospitalized, no limitation on activities
Time frame: Day 28
Percentage of Participants Alive and Discharged From the Hospital by Day 28
Percentage of participants alive and discharged from the hospital on day 28. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities
Time frame: From day 1 up to day 28
Percentage of Participants With Serious Adverse Events
Percentage of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life threatening * Requires inpatient hospitalization * Results in persistent or significant disability * Is a congenital anomaly/birth defect * Is an important medical event
Time frame: From first dose to 60 days post first dose
Percentage of Participants With Serious Adverse Events (SAEs) of the Infections and Infestations System Organ Class
Percentage of participants with Serious Adverse Events (SAEs) of the infections and infestations System Organ Class (SOC)
Time frame: From first dose to 60 days post first dose
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 42 | 19 |
| Completed | 40 | 19 |
| Not completed | 2 | 0 |
| Withdrew: Other reasons | 2 | 0 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 40 | 19 |
| Completed | 34 | 16 |
| Not completed | 6 | 3 |
| Withdrew: Death | 5 | 2 |
| Withdrew: Hospital discharge | 1 | 1 |
The percentage of participants on invasive mechanical ventilation is defined as the delivery of positive pressure to the lungs via an endotracheal tube (or tracheostomy) or death prior to or on day 28.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28 | 30.0 (15.8 to 44.2) | 31.6 (10.7 to 52.5) |
Adjusted mean change from baseline based on the following Ordinal 8-point Clinical Status Scale that was proposed for the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) and is recorded by the worst score (lowest number) state for each day: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, on non-invasive mechanical ventilation or high-flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized, limitation on activities and/or requiring home oxygen; 8. Not hospitalized, no limitation on activities Baseline is defined as the last assessment done prior or on Day 1
| Score on a scale | Abatacept | Placebo |
|---|---|---|
| Adjusted Mean Change From Baseline in the Ordinal 8-Point Clinical Status Scale on Day 28 | 3.20 ± 0.395 | 2.56 ± 0.528 |
Percentage of participants who died due to any cause. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 1) Death
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants Who Died | 12.5 (2.3 to 22.7) | 15.8 (0.0 to 32.2) |
Respiratory failure is defined by the type of resources required as defined by the use of any of these: Mechanical ventilation, extracorporeal membrane oxygenation (ECMO) or oxygen delivery by noninvasive positive pressure or high flow nasal cannula. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants Alive and Free of Respiratory Failure on Day 28±3 | 75.0 (61.6 to 88.4) | 73.7 (53.9 to 93.5) |
Recovery of pulmonary function is assessed by the percentage of participants returned to room air on day 28 after they were oxygen dependent and dependence on oxygen has been noted to be prolonged even after hospital discharge. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 8) Not hospitalized, no limitation on activities
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants Returned to Room Air on Day 28 | 70.0 (55.8 to 84.2) | 57.9 (35.7 to 80.1) |
Percentage of participants alive and discharged from the hospital on day 28. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants Alive and Discharged From the Hospital by Day 28 | 82.5 (70.7 to 94.3) | 73.7 (53.9 to 93.5) |
Percentage of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life threatening * Requires inpatient hospitalization * Results in persistent or significant disability * Is a congenital anomaly/birth defect * Is an important medical event
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants With Serious Adverse Events | 20.0 | 31.6 |
Percentage of participants with Serious Adverse Events (SAEs) of the infections and infestations System Organ Class (SOC)
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) of the Infections and Infestations System Organ Class | 7.5 | 5.3 |
Collected over Adverse Events and Serious Adverse Events were monitored from first dose to 60 days post last dose (Up to approximately 2 months). Participants were assessed for All Cause Mortality from their date of randomization until the study was completed (up to approximately 11 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept | 7/42 (16.7%) | 8/40 (20%) | 8/40 (20%) |
| Placebo | 5/19 (26.3%) | 6/19 (31.6%) | 10/19 (52.6%) |
| Event | Abatacept | Placebo |
|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 4/40 | 4/19 |
| Cardiac arrestCardiac disorders | 3/40 | 2/19 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/40 | 2/19 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/40 | 1/19 |
| SepsisInfections and infestations | 2/40 | 1/19 |
| Acute kidney injuryRenal and urinary disorders | 0/40 | 1/19 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/40 | 1/19 |
| Pneumonia klebsiellaInfections and infestations | 1/40 | 0/19 |
| Pseudomonal sepsisInfections and infestations | 1/40 | 0/19 |
| SeizureNervous system disorders | 1/40 | 0/19 |
| Event | Abatacept | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/40 | 2/19 |
| Oedema peripheralGeneral disorders | 1/40 | 2/19 |
| PyrexiaGeneral disorders | 3/40 | 2/19 |
| HypertensionVascular disorders | 2/40 | 2/19 |
| HypotensionVascular disorders | 0/40 | 2/19 |
| Atrial fibrillationCardiac disorders | 2/40 | 1/19 |
| Mastoid effusionEar and labyrinth disorders | 0/40 | 1/19 |
| Eye haemorrhageEye disorders | 0/40 | 1/19 |
| Catheter site haemorrhageGeneral disorders | 0/40 | 1/19 |
| FatigueGeneral disorders | 0/40 | 1/19 |
| Age, Continuous(Years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 61.1 ± 14.20 | 60.7 ± 14.48 | 61.0 ± 14.17 |
| Sex: Female, Male(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Female | 13 | 6 | 19 |
| Male | 29 | 13 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 9 | 32 |
| Not Hispanic or Latino | 19 | 10 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 4 | 3 | 7 |
| White | 28 | 10 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 4 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2020 to primary completion in Aug 2021, 9 months.
Results were first posted in Oct 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept